April 3rd 2025
View our Q1 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.
Do preschool children with ADHD get the behavioral therapy they need?
April 24th 2022At the 2022 Pediatric Academic Societies meeting, Shruti Mittal, MD, FAAP, looked at how many children with attention-deficit/hyperactivity disorder get started on behavioral therapy before medication in the preschool years.
FDA approves Dyanavel XR for ADHD treatment in kids 6 and older
November 5th 2021In a clinical study of healthy adults, Dyanavel XR tablets were deemed to be bioequivalent to amphetamine extended-release oral suspension in patients with attention-deficit/hyperactivity disorder (ADHD) by the US Food and Drug Administration (FDA).
Prenatal exposure to analgesic opioid linked with elevated risk of ADHD
October 5th 2021A study has found that prenatal analgesic opioid exposure of 5 or more weeks is associated with a slightly elevated risk of attention-deficit/hyperactivity disorder (ADHD) in children compared to exposure of 4 weeks or less.
Hyperactivity, learning disabilities, and social isolation…COVID-19 and its effects on ADHD
October 26th 2020COVID-19 has created many stresses: mental, job-related, and health. For some caregivers, these stressors are complicated further with caring for a child with attention-deficit/hyperactive disorder (ADHD).
Role of relative immaturity in school and ADHD medication use
September 28th 2020Attention-deficit/hyperactivity disorder (ADHD) is marked by age-inappropriate levels of inattention and activity. A report from Finland examines how relative immaturity in the first years of school could increase the risk of ADHD medication use.